Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Identification and Functional Characterization of a Novel CACNA1C -Mediated Cardiac Disorder Characterized by Prolonged QT Intervals With Hypertrophic Cardiomyopathy, Congenital Heart Defects, and Sudden Cardi
Boczek, Nicole J. , Ye, Dan , Jin, Fang , Tester, David J. , Kelcher, April M. Huseby , Bos, J. Martijn , Johnson, Aaron J. , Kanter, Ronald J. , Ackerman, Michael J. , Huseby, April, Kanter, Ronald, Johnson, Aaron J. , Kelcher, April M H , Bos, Johan M

Circulation: Arrhythmia and Electrophysiology | October 20, 2015 | Volume: 8 | Issue: 5 | Pages: 1122-1132

10.1161/circep.115.002745 | PMID 26253506 Get It

Background— A portion of sudden cardiac deaths can be attributed to structural heart diseases, such as hypertrophic cardiomyopathy (HCM) or cardiac channelopathies such as long-QT syndrome (LQTS); however, the underlying molecular mechanisms are distinct. Here, we identify a novel CACNA1C missense mutation with mixed loss-of-function/gain-of-function responsible for a complex phenotype of LQTS, HCM, sudden cardiac death, and congenital heart defects. Methods and Results— Whole exome sequencing in combination with Ingenuity variant analysis was completed on 3 affected individuals and 1 unaffected individual from a large pedigree with concomitant LQTS, HCM, and congenital heart defects and identified a novel CACNA1C mutation, p.Arg518Cys, as the most likely candidate mutation. Mutational analysis of exon 12 of CACNA1C was completed on 5 additional patients with a similar phenotype of LQTS plus a personal or family history of HCM-like phenotypes and identified 2 additional pedigrees with mutations at the same position, p.Arg518Cys/His. Whole cell patch clamp technique was used to assess the electrophysiological effects of the identified mutations in Ca V 1.2 and revealed a complex phenotype, including loss of current density and inactivation in combination with increased window and late current. Conclusions— Through whole exome sequencing and expanded cohort screening, we identified a novel genetic substrate p.Arg518Cys/His-CACNA1C, in patients with a complex phenotype including LQTS, HCM, and congenital heart defects annotated as cardiac-only Timothy syndrome. Our electrophysiological studies, identification of mutations at the same amino acid position in multiple pedigrees, and cosegregation with disease in these pedigrees provide evidence that p.Arg518Cys/His is the pathogenic substrate for the observed phenotype.
Glucose homeostasis after simultaneous pancreas and kidney transplantation: a comparison of subjects with C‐peptide‐positive non‐type 1 diabetes mellitus and type 1 diabetes mellitus
Chakkera, Harini A. , Kudva, Yogish C. , Chang, Yu‐Hui H., Heilman, Raymond L. , Singer, Andrew L., Mathur, Amit K. , Hewitt, Winston R. , Khamash, Hasan , Huskey, Janna L. , Katariya, Nitin , Moss, Adyr A. , Behmen, Senaida, Reddy, Kunam S. , Khamash, Hasan A, Katariya, Nitin N , Chakkera, Harini A

Clinical Transplantation | October 20, 2015 | Volume: 30 | Issue: 1 | Pages: 52-59

10.1111/ctr.12658 | PMID 26485408 Get It

AbstractBackgroundWhile simultaneous pancreas kidney transplant (SPKTx) is a therapeutic option for patients with type 1 diabetes (T1DM) and renal failure, few centers offer SPKTx to “select” non‐T1DM patients. To address concerns that existing insulin resistance may limit the benefits of the pancreas allograft among non‐T1DM, we compared several indices of glucose homeostasis, in “select” non‐T1DM and T1DM patients who received SPKTx.MethodsCriteria for “select” non‐T1DM included the following: positive C‐peptide, BMI <30 kg/m2, treatment with oral agents before insulin initiation, and insulin at <1 unit/kg/d. We compared several indices of glucose homeostasis within 1 yr post‐SPKTx among seven “select” patients with non‐T1DM and nine patients with T1DM with similar age, BMI, and immunosuppression. Measurements of insulin resistance included the following: homeostatic model, insulin sensitivity index, and insulin–glucose ratio; insulin secretion measures included the following: corrected insulin response.ResultsNon‐T1DM had similar pre‐transplant metabolic (fasting glucose, HbA1c, blood pressure, and lipid) parameters to the T1DM cohort. There were no significant differences in the various measures of insulin resistance and secretion between T1DM and “select” non‐T1DM patients.ConclusionOur results suggest SPKTx should be considered in the therapeutic armamentarium among carefully select non‐T1DM with features of minimal insulin resistance; however, a larger cohort with longer follow‐up is needed to confirm our results.
Response to Letters Regarding Article, “Coronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction”
Mohammed, Selma F. , Redfield, Margaret M.

Circulation | October 20, 2015 | Volume: 132 | Issue: 16 | Pages: No page available

10.1161/circulationaha.115.017050 | PMID 26481572 Get It

Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting
Kalman, LV, Agúndez, JAG, Appell, Malin Lindqvist , Black, J.H., Bell, GC, Boukouvala, Sotiria , Bruckner, Carsten, Bruford, Elspeth A. , Caudle, KE, Coulthard, SA, Daly, Ann K. , Tredici, AL Del, Dunnen, Johan T. den , Drozda, Katarzyna, Everts, Robin E. , Flockhart, David A., Freimuth, Robert R. , Hachad, Houda , Hartshorne, Toinette, Ingelman‐Sundberg, Magnus , Klein, Teri E. , Lauschke, Volker M. , Maglott, DR, McLeod, HL, McMillin, GA, Ua, Meyer, Dj, Müller, Nickerson, D. A., Oetting, WS , Pacanowski, MA, Vm, Pratt, Relling, MV, Roberts, Angharad M. , Ws, Rubinstein, Sangkuhl, Katrin , Schwab, Matthias , Scott, Stuart A. , Sim, SC, Thirumaran, RK, Toji, LH, Tyndale, Rachel F. , Schaik, RHN van, Whirl‐Carrillo, Michelle , Yeo, K. L. B., Zanger, UM, Agúndez, José A. G. , Müller, Daniel J. , Agúndez, JAG, Gaedigk, Andrea , Relling, Mary V. , Toji, Lorraine H., Whirl-Carrillo, Michelle , Agúndez, José A G , Hachad, Houda , Müller, Daniel J , Tyndale, Rachel F , Freimuth, Robert R , Klein, Teri E , Scott, Stuart A , Schwab, Matthias

Clinical Pharmacology & Therapeutics | October 20, 2015 | Volume: 99 | Issue: 2 | Pages: 172-185

10.1002/cpt.280 | PMID 26479518 Get It

This article provides nomenclature recommendations developed by an international workgroup to increase transparency and standardization of pharmacogenetic (PGx) result reporting. Presently, sequence variants identified by PGx tests are described using different nomenclature systems. In addition, PGx analysis may detect different sets of variants for each gene, which can affect interpretation of results. This practice has caused confusion and may thereby impede the adoption of clinical PGx testing. Standardization is critical to move PGx forward.
Laparoscopic Repair of Incisional and Other Complex Abdominal Wall Hernias
Craft, Randall O., Harold, Kristi L.

The Permanente Journal | October 20, 2015 | Volume: 13 | Issue: 3 | Pages: 38-42

10.7812/tpp/09-001 | PMID 20740087 Get It

Neurogenic orthostatic hypotension: roles of norepinephrine deficiency in its causes, its treatment, and future research directions
Loavenbruck, Adam , Sandroni, Paola

Current Medical Research and Opinion | October 20, 2015 | Volume: 31 | Issue: 11 | Pages: 2095-2104

10.1185/03007995.2015.1087988 | PMID 26373628 Get It

Multifaceted interventions to decrease mortality in patients with severe sepsis/septic shock—a quality improvement project
Elmer, Jennifer, Dannielson, Richard, Brown, Catherine , Ramar, Kannan , Siontis, Brittany, Park, John , Siontis, Brittany L. , Park, Cheol Ho , Surani, Salim

PeerJ | October 20, 2015 | Volume: 3 | Issue: No issue available | Pages: e1290

10.7717/peerj.1290 | PMID 26500811 Get It

Despite knowledge that EGDT improves outcomes in septic patients, staff education on EGDT and compliance with the CPOE order set has been variable. Based on results of a resident survey to identify barriers to decrease severe sepsis/septic shock mortality in the medical intensive care unit (MICU), multifaceted interventions such as educational interventions to improve awareness to the importance of early goal-directed therapy (EGDT), and the use of the Computerized Physician Order Entry (CPOE) order set, were implemented in July 2013. CPOE order set was established to improve compliance with the EGDT resuscitation bundle elements. Orders were reviewed and compared for patients admitted to the MICU with severe sepsis/septic shock in July and August 2013 (controls) and 2014 (following the intervention). Similarly, educational slide sets were used as interventions for residents before the start of their ICU rotations in July and August 2013. While CPOE order set compliance did not significantly improve (78% vs. 76%, p = 0.74), overall EGDT adherence improved from 43% to 68% ( p = 0.0295). Although there was a trend toward improved mortality, this did not reach statistical significance. This study shows that education interventions can be used to increase awareness of severe sepsis/septic shock and improve overall EGDT adherence.
Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis
Nevens, Frederik , Torres, Vicente E. , Hogan, Marie C. , Drenth, Joost P.H. , Gevers, Tom J.G. , Torres, Vicente E , Hogan, Marie C , Drenth, Joost P H

Liver International | October 20, 2015 | Volume: 36 | Issue: 4 | Pages: 595-602

10.1111/liv.12986 | PMID 26481454 Get It

AbstractBackground & AimsSomatostatin analogues reduce liver volumes in polycystic liver disease. However, patients show considerable variability in treatment responses. Our aim was to identify specific patient, disease or treatment characteristics that predict response in polycystic liver disease during somatostatin analogue therapy.MethodsWe pooled the individual patient data of four trials that evaluated long‐acting somatostatin analogues (120 mg lanreotide or 40 mg octreotide) for 6–12 months in polycystic liver disease patients. We performed uni‐ and multivariate linear regression analysis with preselected patient, disease and drug variables to identify independent predictors of response, defined as per cent change in liver or kidney volume (in ADPKD subgroup). All analyses were adjusted for baseline liver volume and centre.ResultsWe included 153 polycystic liver disease patients (86% female, median liver volume 4974 ml) from three international centres, all treated with octreotide (n = 70) or lanreotide (n = 83). Mean reduction in liver volume was 4.4% (range −31.6 to +9.4%). Multivariate linear regression revealed that elevated baseline alkaline phosphatase was associated with increased liver volume reduction during therapy (−2.7%, 95% CI −5.1 to −0.2%, P = 0.04), independently of baseline liver volume. Somatostatin analogue type, underlying diagnosis and eGFR did not affect response. In our ADPKD subpopulation (n = 100), elevated alkaline phosphatase predicted liver volume reduction (−3.2%, P = 0.03) but did not predict kidney volume reduction (+0.1%, P = 0.97). Total gastro‐intestinal symptom severity decreased with therapy in a subgroup analysis (n = 95; P < 0.001).ConclusionAlkaline phosphatase is a liver‐specific, independent predictor of response in polycystic liver disease during somatostatin analogue therapy.
Robotic Mitral Valve Repair for Simple and Complex Degenerative Disease
Suri, Rakesh M. , Taggarse, Amit, Burkhart, Harold M. , Daly, Richard C. , Mauermann, William J., Li, Zhuo , Enriquez‐Sarano, Maurice , Li, Zhuo , Mauermann, William, Nishimura, Rick A. , Li, Zhuo, Dearani, Joseph A. , Michelena, Héctor I. , Enriquez-Sarano, Maurice

Circulation | October 20, 2015 | Volume: 132 | Issue: 21 | Pages: 1961-1968

10.1161/circulationaha.115.017792 | PMID 26481775 Get It

Background— Severe primary (degenerative) mitral regurgitation (MR) is repaired with durable results when simple single-scallop disease is addressed. The midterm quality outcomes of minimally invasive repair for complex disease are unknown, however. Methods and Results— From January 2008 to January 2015, 487 patients (56±11 years, 360 men, ejection fraction 65±6%, 98.8% complete follow-up) underwent robotic mitral valve repair for severe nonischemic degenerative MR. Simple pathology was addressed in 289 of 487 (59%) patients, and complex repair (all others) was performed in 198 of 487 (41%). Four patients died during follow-up with a 5-year survival rate 99.5% (99.4% simple; 99.5% complex; hazard ratio, 0.48; 95% confidence interval, 0.05–4.59); and New York Heart Association functional class I/II was documented in 97.9% (477/487). Eight patients had recurrence of moderate-to-severe MR (4 simple, 4 complex), with a 5-year freedom from MR of 94.6% (96.2% simple; 92.7%, complex; P =0.67; hazard ratio, 1.36; 95% confidence interval, 0.34–5.43). Seven patients (2 simple, 5 complex), underwent mitral reoperation, with a 5-year freedom from reoperation of 97.7% (99.1% simple; 95.7% complex; P =0.13; hazard ratio, 3.35; 95% confidence interval, 0.65–17.32). Conclusions— At a large tertiary care referral center, midterm quality outcomes after robotic correction of degenerative MR are excellent, with very high survival, infrequent complications, and a low likelihood of MR recurrence, regardless of mitral valve repair complexity. Awareness of these improvements in outcome is important to inform contemporary decisions regarding high-quality alternatives to conventional and percutaneous mitral repair.
Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients
Hu, Chunling , Hart, Steven N. , Bamlet, William R. , Moore, Raymond M. , Nandakumar, Kannabiran, Eckloff, Bruce W., Petersen, Gloria M. , Lee, Yean K, McWilliams, Robert R. , Lee, Yean Kee , Couch, Fergus J. , Bamlet, William R , Hart, Steven N , Hu, Chunling , Moore, Raymond

Cancer Epidemiology, Biomarkers & Prevention | October 20, 2015 | Volume: 25 | Issue: 1 | Pages: 207-211

10.1158/1055-9965.epi-15-0455 | PMID 26483394 Get It

Abstract The prevalence of germline pathogenic mutations in a comprehensive panel of cancer predisposition genes is not well-defined for patients with pancreatic ductal adenocarcinoma (PDAC). To estimate the frequency of mutations in a panel of 22 cancer predisposition genes, 96 patients unselected for a family history of cancer who were recruited to the Mayo Clinic Pancreatic Cancer patient registry over a 12-month period were screened by next-generation sequencing. Fourteen pathogenic mutations in 13 patients (13.5%) were identified in eight genes: four in ATM, two in BRCA2, CHEK2, and MSH6, and one in BARD1, BRCA1, FANCM, and NBN. These included nine mutations (9.4%) in established pancreatic cancer genes. Three mutations were found in patients with a first-degree relative with PDAC, and 10 mutations were found in patients with first- or second-degree relatives with breast, pancreas, colorectal, ovarian, or endometrial cancers. These results suggest that a substantial proportion of patients with PDAC carry germline mutations in predisposition genes associated with other cancers and that a better understanding of pancreatic cancer risk will depend on evaluation of families with broad constellations of tumors. These findings highlight the need for recommendations governing germline gene-panel testing of patients with pancreatic cancer. Cancer Epidemiol Biomarkers Prev; 25(1); 207–11. ©2015 AACR.